OncoCyte (OCX) Competitors $3.18 +0.45 (+16.30%) Closing price 06/17/2025Extended Trading$3.18 0.00 (0.00%) As of 06/17/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX vs. HUMA, AMRN, PRTA, BNTC, HRTX, SNDL, VOR, AURA, ATXS, and AVTEShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Humacyte (HUMA), Amarin (AMRN), Prothena (PRTA), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), SNDL (SNDL), Vor Biopharma (VOR), Aura Biosciences (AURA), Astria Therapeutics (ATXS), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Its Competitors Humacyte Amarin Prothena Benitec Biopharma Heron Therapeutics SNDL Vor Biopharma Aura Biosciences Astria Therapeutics Aerovate Therapeutics Humacyte (NASDAQ:HUMA) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership. Do institutionals and insiders hold more shares of HUMA or OCX? 44.7% of Humacyte shares are held by institutional investors. Comparatively, 55.3% of OncoCyte shares are held by institutional investors. 5.1% of Humacyte shares are held by insiders. Comparatively, 2.1% of OncoCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to HUMA or OCX? In the previous week, Humacyte had 11 more articles in the media than OncoCyte. MarketBeat recorded 11 mentions for Humacyte and 0 mentions for OncoCyte. Humacyte's average media sentiment score of 0.53 beat OncoCyte's score of 0.00 indicating that Humacyte is being referred to more favorably in the media. Company Overall Sentiment Humacyte Positive OncoCyte Neutral Which has more risk & volatility, HUMA or OCX? Humacyte has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Do analysts rate HUMA or OCX? Humacyte presently has a consensus target price of $11.71, suggesting a potential upside of 407.11%. OncoCyte has a consensus target price of $6.06, suggesting a potential upside of 90.94%. Given Humacyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Humacyte is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00OncoCyte 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is HUMA or OCX more profitable? Humacyte has a net margin of 0.00% compared to OncoCyte's net margin of -1,516.06%. Humacyte's return on equity of 0.00% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A -73.59% OncoCyte -1,516.06%-215.59%-27.23% Which has stronger valuation & earnings, HUMA or OCX? OncoCyte has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than OncoCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$517K693.08-$148.70M-$0.69-3.35OncoCyte$3.84M23.63-$60.66M-$3.53-0.90 SummaryHumacyte beats OncoCyte on 12 of the 17 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.80M$7.32B$5.55B$9.09BDividend YieldN/A2.85%5.07%4.03%P/E Ratio-0.9034.5428.2520.32Price / Sales23.6330.72431.56110.05Price / CashN/A24.5226.2427.98Price / Book-4.548.258.125.50Net Income-$60.66M$236.06M$3.19B$250.38M7 Day PerformanceN/A0.93%3.68%2.19%1 Month Performance19.81%2.76%7.70%10.92%1 Year Performance-4.65%33.80%29.39%16.41% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte1.9019 of 5 stars$3.18+16.3%$6.06+90.9%-4.7%$90.80M$3.84M-0.90120HUMAHumacyte2.2023 of 5 stars$2.16-5.3%$11.71+442.3%-67.0%$353.67M$1.57M-3.13150AMRNAmarin0.429 of 5 stars$16.65-0.5%$12.00-27.9%+8.4%$346.43M$228.61M-4.57360Positive NewsPRTAProthena3.6123 of 5 stars$6.29-2.2%$31.50+400.8%-71.5%$346.38M$135.16M-3.02130BNTCBenitec Biopharma1.7523 of 5 stars$13.49+2.4%$23.83+76.7%+35.0%$345.72M$80K-8.9320High Trading VolumeHRTXHeron Therapeutics3.6616 of 5 stars$2.15-2.3%$5.00+132.6%-32.7%$335.64M$144.29M-35.83300SNDLSNDL3.0232 of 5 stars$1.24-2.4%$3.63+192.3%-35.3%$333.73M$671.81M-4.282,516VORVor Biopharma3.9157 of 5 stars$2.67+39.8%$5.63+110.8%+163.2%$333.64MN/A-1.62140Options VolumeHigh Trading VolumeAURAAura Biosciences2.5859 of 5 stars$6.16-6.1%$22.00+257.1%-25.2%$329.76MN/A-3.2450ATXSAstria Therapeutics1.7576 of 5 stars$6.20+6.7%$30.00+383.9%-44.4%$327.88MN/A-3.3230AVTEAerovate TherapeuticsN/A$11.14+3.1%N/A-84.5%$322.89MN/A-3.7320High Trading Volume Related Companies and Tools Related Companies Humacyte Alternatives Amarin Alternatives Prothena Alternatives Benitec Biopharma Alternatives Heron Therapeutics Alternatives SNDL Alternatives Vor Biopharma Alternatives Aura Biosciences Alternatives Astria Therapeutics Alternatives Aerovate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
